Printer Friendly

TOP RESEARCHER JOINS THE LIPOSOME COMPANY CELL ADHESION SCIENTIFIC ADVISORY BOARD

 TOP RESEARCHER JOINS THE LIPOSOME COMPANY
 CELL ADHESION SCIENTIFIC ADVISORY BOARD
 PRINCETON, N.J., Feb. 18 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO) announced today that Michael P. Bevilacqua, M.D., Ph.D., has joined its Cell Adhesion Scientific Advisory Board.
 Bevilacqua is perhaps best known for the discovery of endothelial leukocyte adhesion molecule-1 (ELAM-1), which is one of the main receptors on endothelial cells responsible for the adhesion to neutrophils. Endothelial cells line the walls of blood vessels, and neutrophils are a type of white blood cell. Neutrophil adhesion (or binding) to endothelial cells is a key step in a complicated set of cellular and molecular processes that ultimately leads to inflammation and tissue destruction. These events occur in a broad range of disease conditions, including Arthritis, Adult Respiratory Distress Syndrome (ARDS), Septic Shock, and reperfusion injury following heart attacks. By providing insight into the mechanism by which endothelial cells and neutrophils bind to each other, Bevilacqua's discovery and description of ELAM-1 and other adhesion receptors has opened up exciting new approaches to controlling and preventing the inflammatory process involved in these and many other disease conditions.
 Bevilacqua is currently an investigator in the Howard Hughes Medical Institute and an Associate Professor of Pathology at University of California, San Diego. He received a B.A. in Biology from the University of Pennsylvania in 1976, and both M.D. and Ph.D. degrees from the State University of New York, Downstate Medical Center, in 1982. Prior to accepting his present position in the Fall of 1991, Bevilacqua spent nine years at Brigham and Women's Hospital and Harvard Medical School. He is a member of many professional societies, and has received numerous awards and honors, including the Louis N. Katz Basic Science Research Prize for Young Investigators, awarded by the American Heart Association, for his discovery of ELAM-1.
 The Liposome Company's Cell Adhesion Scientific Advisory Board meets regularly to advise the company on the research and development of drugs to treat inflammatory and vaso-occlusive disease conditions. The company's TLC C-53, a liposomal prostagiandin E1, (PGE1), is being developed for the treatment of Adult Respiratory Distress Syndrome (ARDS), Sepsis/Trauma Syndrome, Acute Myocardial Infarction (AMI), and as a means to prevent restenosis following angioplasty. The Liposome Company expects to file an Investigational New Drug (IND) application in mid-1992.
 Other members of the Liposome Company's Cell Adhesion Scientific Advisory Board include;
 -- Gerald Weissmann, M.D., (chairman) professor of Medicine, director, Division of Rheumatology, New York University Medical Center;
 -- Ralph L. Nachman, M.D., professor and chairman, Department of Medicine, Cornell University Medical College;
 -- John Repine, M.D., professor of Medicine, University of Colorado Health Science Center, and director, Webb-Waring Lung Institute;
 -- Bengt Samuelsson, M.D., Ph.D., professor and president, Karolinska Institute, Nobel Laureate in Medicine (1982); and
 -- James Willerson, M.D., professor and chairman, Department of Internal Medicine, University of Texas Medical School.
 A leading company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, the Liposome Company selectively develops proprietary parenteral pharmaceuticals for the treatment, prevention and diagnosis of life-threatening illnesses.
 -0- 2/18/92
 /CONTACT: Marc J. Ostro, vice chairman and chief science officer of Liposome Company, 609-452-7060/
 (LIPO) CO: Liposome Company, Inc. ST: New Jersey IN: MTC SU: PER


TS-OS -- NY025 -- 9842 02/18/92 10:36 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 18, 1992
Words:550
Previous Article:FIRST AUSTRALIA PRIME INCOME FUND ANNOUNCES DIVIDEND
Next Article:IBM ANNOUNCES POWERFUL NEW AS/400 PROCESSORS, NEW SOFTWARE, FIRST USE OF 16-MEGABIT CHIP
Topics:


Related Articles
LIPOSOME COMPANY REPORTS THIRD QUARTER RESULTS; THIRD QUARTER REVENUES UP 151.6 PERCENT
LIPOSOME ACQUIRES CLOT-BUSTER TECHNOLOGY FOR HEART ATTACKS; PATENT TO COVER LIPOSOME-ENCAPSULATED FIBRINOLYTIC AGENTS FOR ARTERY REOPENING
THE LIPOSOME COMPANY GAINS PATENT FOR LIPOSOMAL PROSTAGLANDIN; TLC C-53 BEING DEVELOPED FOR ARDS, SEPSIS/TRAUMA SYNDROME, AMI AND ANGIOPLASTY
LIPOSOME COMPANY COMPLETES STOCK OFFERING OF 3 MILLION SHARES
THE LIPOSOME COMPANY SELLS ADDITIONAL 450,000 SHARES AS PART OF STOCK OFFERING
THE LIPOSOME COMPANY APPOINTS DAVID SHAND TO BOARD OF DIRECTORS
ANDREW JANOFF AND JOEL PORTNOFF NAMED VICE PRESIDENTS AT THE LIPOSOME COMPANY
TCELL SCIENCES PRESENTS INITIAL DATA ON NOVEL COMPLEMENT/CELL ADHESION INHIBITOR FOR THE TREATMENT OF INFLAMMATORY CONDITIONS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters